Abstract Search

ea0077op2.1 | Adrenal and Cardiovascular | SFEBES2021

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [¹⁸F]CETO in healthy volunteers and patients with primary aldosteronism

Senanayake Russell , Gillett Daniel , Bashari Waiel , MacFarlane James , Hu Lihua , Palma August , Aloj Luigi , Mendichovszky Iosif , Hader Stefan , Boros Istvan , Brown Morris , Cheow Heok , Aigbirhio Franklin , Gurnell Mark

Background: Primary aldosteronism (PA) is an important, potentially curable, cause of hypertension. Distinguishing unilateral and bilateral causes is a critical step in determining who should be considered for adrenalectomy. Adrenal vein sampling (AVS) remains the gold standard for lateralisation. However, AVS is technically challenging with limited availability. To address this, we have introduced molecular imaging using PET/CT with the radiotracer [11C]Metomidate ...

1 shares

ea0086op2.1 | Adrenal and Cardiovascular | SFEBES2022

Novel radiolabeled ligand, Para-chloro-2-[¹⁸F]fluoroethyletomidate (CETO) compared to [¹¹C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Goodchild Emily , Senanayake Russell , Wu Xilin , Bashari Waiel , Salsbury Jackie , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Gillett Dan , Boros Istvan , Aigbirhio Franklin , Sadhev Anju , Bird Nicholas , Hader Stefan , Warnes Victoria , Cruickshank Kennedy , Cheow Heok , Drake William , Gurnell Mark , Brown Morris

Introduction: Our MATCH study demonstrated 11-C ligand MTO was non-inferior to adrenal vein sampling in predicting surgical outcomes of adrenalectomy in patients with PA. The 20-min half-life of 11-C imposes logistic constraints. We investigated an 18-F ligand, CETO; its 2h half-life permits use in any facility with fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan capability.Objective: To compare the detection of aldosterone-producing ade...

0 shares

ea0086op2.3 | Adrenal and Cardiovascular | SFEBES2022

Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

Goodchild Emily , Wu Xilin , Senanayake Russell , Bashari Waiel , Salsbury Jackie , Cabrera Claudia , Argentesi Giulia , O'Toole Samuel , MacFarlane James , Laycock Kate , Benu Daniela , Matson Matthew , Koo Brendan , Parvanta Laila , Hilliard Nick , Kosmoliaptsis Vasilis , Marker Alison , Berney Daniel , Tan Wilson , Foo Roger , Mein Charles , Wozniak Eva , Savage Emmanuel , Sahdev Anju , Bird Nicholas , Boros Istvan , Hader Stefan , Warnes Victoria , Gillett Dan , Dawnay Anne , Adeyeye Elizabeth , Prete Alessandro , Taylor Angela , Wiebke Arlt , Bhuva Anish , Aigbirhio Franklin , Manisty Charlotte , Cruickshank Kennedy , Cheow Heok , Gurnell Mark , Drake William , Brown Morris

Introduction: In a prospective within-patient study (MATCH) 11C-metomidate PET-CT (MTO) was an accurate non-invasive alternative to adrenal vein sampling in the detection of unilateral PA1. Post-adrenalectomy (ADX), 24/78 (30%) patients achieved complete clinical success (PASO consensus) at 6 months, but 75% achieved reduction in B-type natriuretic peptide (BNP).Aim: To determine: 1. the number of patients who sustain complete clinical success...

0 shares

Endocrine Abstracts

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [¹⁸F]CETO in healthy volunteers and patients with primary aldosteronism

Novel radiolabeled ligand, Para-chloro-2-[¹⁸F]fluoroethyletomidate (CETO) compared to [¹¹C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

BiosciAbstracts

Endocrine Abstracts

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [18F]CETO in healthy volunteers and patients with primary aldosteronism

Novel radiolabeled ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) compared to [11C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)

Complete clinical cure of primary aldosteronism (PA) is predictable and sustained for at least two years

BiosciAbstracts

A phase 1 clinical trial evaluating the safety and efficacy of up to two administrations of the adrenal PET tracer [¹⁸F]CETO in healthy volunteers and patients with primary aldosteronism

Novel radiolabeled ligand, Para-chloro-2-[¹⁸F]fluoroethyletomidate (CETO) compared to [¹¹C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)